ClinicalTrials.Veeva

Find clinical trials for Breast Cancer in Milano, Lombardia

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Triple Negative Breast Cancer
Cancer
Carcinoma
Endometrial Cancer
Squamous Cell Carcinoma of Head and Neck
Non-Small-Cell Lung Carcinoma
Lung Cancer

Breast Cancer trials near Milano, Lombardia, ITA:

CAELYX® as Adjuvant Treatment in Early Stage Luminal B Breast Cancer BREAST CANCER

adjuvant chemotherapy regimen in patients with early-stage luminal B breast cancer.The primary endpoint will be to evaluate the fea...

Active, not recruiting
Breast Cancer
Drug: Caelyx®

Phase 2

European Institute of Oncology

Milan, Italy

Breast cancer is the most common form of cancer among women. For patients candidated for adjuvant chemotherapy and endocri...

Active, not recruiting
Breast Cancer
Drug: Anastrozole or Letrozole or Exemestane

Phase 3

IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy

Milano, MI, Italy and 73 other locations

adjuvant systemic treatment instead of adjuvant chemotherapy followed by endocrine therapy in older patients with stage II-III ER+/HER2- early breast...

Active, not recruiting
Breast Cancer Stage II
Breast Cancer Stage III
Drug: doxorubicin/cyclophosphamide
Drug: Docetaxel / cyclophosphamide

Phase 2

European Organisation for Research and Treatment of Cancer (EORTC)

Monza, Italy and 72 other locations

This study will compare DS 8201a to standard treatment.Participants must have HER2 breast cancer that has been treated before.Their ...

Active, not recruiting
Breast Cancer
Drug: Trastuzumab
Drug: Trastuzumab deruxtecan

Phase 3

Daiichi Sankyo

Milano, Italy and 226 other locations

DESTINY-Breast07 will investigate the safety, tolerability, and anti-tumour activity of trastuzumab deruxtecan (T-DXd) in combination with o ...

Active, not recruiting
Metastatic Breast Cancer
Drug: Paclitaxel
Drug: Tucatinib

Phase 1, Phase 2

AstraZeneca
AstraZeneca

Milan, Italy and 71 other locations

-positive / HER2-negative breast cancer which has spread beyond the original tumor and/or to other organs.During this study, anti-h...

Enrolling
Breast Cancer Recurrent
Drug: Standard endocrine therapy
Drug: Palbociclib 125mg

Phase 3

ETOP IBCSG Partners Foundation

Milan, Italy and 52 other locations

This study will be conducted in patients with metastatic breast cancer who have specific Fibroblast Growth Factor Receptor gene abn...

Active, not recruiting
Metastatic Breast Cancer
FGFR 1 High Amplification
Drug: Futibatinib
Drug: Futibatinib plus Fulvestrant

Phase 2

Taiho Pharma
Taiho Pharma

Milano, Italy and 36 other locations

dose of MEN1611 to be used in combination with Trastuzumab with/without Fulvestrant for the treatment of advanced or metastatic HER2-positive breast...

Active, not recruiting
Advanced or Metastatic Breast Cancer
Drug: Fulvestrant
Drug: MEN1611

Phase 1

Menarini
Menarini

Milan, Italy and 26 other locations

to anti-HER2-based therapy plus endocrine therapy alone in improving the outcomes of subjects with hormone receptor-positive, HER2+ metastatic breast...

Active, not recruiting
Estrogen Receptor Positive Breast Cancer
HER-2 Positive Breast Cancer
Drug: palbociclib
Drug: trastuzumab

Phase 3

Alliance Foundation Trials (AFT)

Milano, Italy and 114 other locations

A study to learn about a new medicine called ARV-471 (PF-07850327) in people who have advanced metastatic breast cancer....

Enrolling
Advanced Breast Cancer
Drug: Fulvestrant
Drug: ARV-471

Phase 3

Pfizer
Pfizer

Milano, Italy and 324 other locations

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems